Implication of Sulfonylurea Derivatives As Prospective Inhibitors of Human Carbonic Anhydrase II
Overview
Authors
Affiliations
Selective carbonic anhydrase (CA) inhibitors have gained a lot of importance owing to the implication of specific isoforms of CA in certain diseases like glaucoma, leukemia, cystic fibrosis, and epilepsy. A novel class of sulfonylurea derivatives was synthesized from corresponding sulfonyl chlorides and amines. Compounds with different pendant moieties in the sulfonylurea derivatives show significant interactions with human carbonic anhydrase II (CAII). In vitro evaluation of the sulfonylurea derivatives revealed that three compounds possess admirable inhibitory activity against CAII. Compounds containing methyl (G2), isopropyl (G4) and o-tosyl (G5) groups displayed IC (109-137 μm) for CAII. Fluorescence binding and cytotoxicity studies revealed that these compounds are showing good binding affinity (18-34 μM) to CAII and non- toxic to human cells. Further, molecular docking studies of G2, G4 and G5 with CAII showed that these compounds fit nicely in the active site of CAII. Molecular dynamics simulation studies of these compounds complexed with CAII showed that essential interactions were maintained up to 50 ns of simulation. These results indicate the promising nature of the sulfonylurea scaffold towards CAII inhibition and opens scope of hit to-lead optimization for discovery of effective drugs against CAII-associated disorders.
Thanh N, Toan V, Trang V RSC Med Chem. 2025; .
PMID: 39823041 PMC: 11734695. DOI: 10.1039/d4md00816b.
Wu S, Zhou X, Li F, Sun W, Zheng Q, Liang D Int J Mol Sci. 2024; 25(6).
PMID: 38542320 PMC: 10969960. DOI: 10.3390/ijms25063348.
Thanh N, Toan V, Giang N, Thi Kim Van H, Son Hai D, Minh Tri N RSC Med Chem. 2023; 14(12):2751-2767.
PMID: 38107183 PMC: 10718584. DOI: 10.1039/d3md00508a.
Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?.
Stoner A, Harris A, Oddone F, Belamkar A, Verticchio Vercellin A, Shin J Br J Ophthalmol. 2021; 106(10):1332-1337.
PMID: 34433550 PMC: 8936059. DOI: 10.1136/bjophthalmol-2021-319530.
Roy S, Mahapatra A, Mohammad T, Gupta P, Alajmi M, Hussain A Pharmaceuticals (Basel). 2020; 13(6).
PMID: 32526899 PMC: 7346089. DOI: 10.3390/ph13060118.